SAN FRANCISCO — Moving glaucoma innovation to focus on early treatment will save money and improve patient quality of life, according to the keynote speaker at the Glaucoma Research Foundation’s Glaucoma 360 New Horizons Forum here. Paul P. Lee, MD, JD, gave the Drs. Henry and Frederick Sutro Memorial Lecture on transcendental goals for innovation in eye health.
Macular degeneration is a major cause of irreversible vision loss in the United States and around the world. As many as 11 million Americans have some form of macular degeneration.
Today, so-called conventional corneal collagen cross-linking has become the gold standard to halt the course of progressive keratoconus. In this photoreticulation technique, the collagen fibers are bonded with the surrounding corneal matrix. Chemical t…
Researchers from Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology’s Program in Speech and Hearing Bioscience and Technology have demonstrated that salicylates, a class of non-steroidal inflammatory drugs (…
Status: Not yet recruiting,
Condition Summary: Eye Diseases
SAN FRANCISCO – At the New Horizons Forum during Glaucoma 360, Joel S. Schuman, MD, discusses the broadening array of glaucoma drug delivery devices in development.